tiprankstipranks
Regeneron reports Q1 adjusted EPS $9.55, consensus $10.10
PremiumThe FlyRegeneron reports Q1 adjusted EPS $9.55, consensus $10.10
7d ago
Notable companies reporting before tomorrow’s open
PremiumThe Fly
Notable companies reporting before tomorrow’s open
7d ago
Notable companies reporting before tomorrow’s open
PremiumThe Fly
Notable companies reporting before tomorrow’s open
7d ago
Regeneron, Mammoth collaborate to purse next-generation gene editing
PremiumThe FlyRegeneron, Mammoth collaborate to purse next-generation gene editing
13d ago
Regeneron to Showcase Progress in Advancing Novel Investigational Treatment Approaches for a Broad Range of Solid Tumors and Blood Cancers at ASCO
PremiumPress Releases
Regeneron to Showcase Progress in Advancing Novel Investigational Treatment Approaches for a Broad Range of Solid Tumors and Blood Cancers at ASCO
14d ago
Regeneron price target raised to $1,030 from $1,020 at TD Cowen
PremiumThe Fly
Regeneron price target raised to $1,030 from $1,020 at TD Cowen
14d ago
DOJ files false claims act complaint against Regeneron over drug pricing
PremiumThe FlyDOJ files false claims act complaint against Regeneron over drug pricing
28d ago
Regeneron presents pivotal data from Phase 1/2 LINKER-MM1 trial of linvoseltamab
PremiumThe Fly
Regeneron presents pivotal data from Phase 1/2 LINKER-MM1 trial of linvoseltamab
1M ago
Linvoseltamab Pivotal Data Presented at AACR Reinforce High Response Rate that Deepens Over Time in Patients with Heavily Pre-Treated Multiple Myeloma
PremiumPress Releases
Linvoseltamab Pivotal Data Presented at AACR Reinforce High Response Rate that Deepens Over Time in Patients with Heavily Pre-Treated Multiple Myeloma
1M ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100